Comparative Pharmacology
Head-to-head clinical analysis: DEPO MEDROL versus FLUDROCORTISONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPO MEDROL versus FLUDROCORTISONE ACETATE.
DEPO-MEDROL vs FLUDROCORTISONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylprednisolone acetate is a synthetic glucocorticoid receptor agonist that modulates gene expression to suppress inflammation, immune responses, and adrenal function by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
IV: 10-40 mg every 1-2 weeks; IM: 40-120 mg every 1-4 weeks; Intra-articular/soft tissue: 4-80 mg per injection, repeat every 1-5 weeks as needed.
0.1 mg orally once daily, range 0.05-0.2 mg/day
None Documented
None Documented
Plasma terminal elimination half-life: 2.5-4.0 hours (methylprednisolone acetate formulation). Duration of adrenal suppression correlates with tissue esterase hydrolysis and prolonged tissue retention.
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
Primarily hepatic metabolism; renal excretion of metabolites (<10% unchanged). Fecal excretion is minor (<5%).
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Category C
Category D/X
Corticosteroid
Corticosteroid